(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 February 2005 (17.02.2005)

(10) International Publication Number
WO 2005/013932 A1


(21) International Application Number: PCT/EP2004/008572

(22) International Filing Date: 30 July 2004 (30.07.2004)

(25) Filing Language: English

(26) Publication Language: English


(71) Applicant (for all designated States except US): GIULIANI S.P.A. [IT/IT]; Via P. Palagi, 2, I-20129 Milano (IT).

(72) Inventors: RINALDI, Fabio [IT/IT]; Via Benvenuto Cellini, 8, I-20129 Milano (IT).
SORBELLINI, Elisabetta [IT/IT]; Via Parri, 6, I-20060 Mediglia (IT).
BARONI, Sergio [IT/IT]; Via Piazzolo, 3, I-24030 Villa d’Adda (IT).
BENEDUSI, Anna [IT/IT]; Via N. Sauro, 9, I-20124 Milano (IT).

(74) Agent: APPOLONI, Romano; Notarbartolo & Gervasi S.p.A., Corso di Porta Vittoria, 9, I-20122 Milan (IT).

(54) Title: USE OF SPERMINE AND/OR SPERMIDINE AGAINST SKIN AGETING IN DIETARY, PHARMACEUTICAL OR COSMETIC COMPOSITIONS

(57) Abstract: The invention concerns the use of spermine and spermidine as active ingredients in the preparation of a composition for dietary, pharmaceutical or cosmetic use in humans for health and beauty of the skin and skin appendages, and related compositions for pharmaceutical or dietary or cosmetic use for administration to humans.
DESCRIPTION

The present invention concerns a new use of the polyamines called spermine (N,N'-bis(3-aminopropyl)tetramethylenediamine) and spermidine (N-(3-aminopropyl)tetramethylenediamine).

It is known in literature that compounds belonging to the class of aliphatic polyamines perform a decisive role in control of the biological mechanisms of growth, division, differentiation of cells and proliferation of animal tissues.

The polyamines in question comprise essentially the compounds putrescine, spermine and spermidine. The latter two owe their name to the fact that they were discovered for the first time in human sperm. In reality spermidine is present in practically all the body fluids (blood, saliva, tears, milk). Subsequently spermidine was found also in many foods both of animal origin (meat, fish, eggs, milk, cheese) and vegetable origin (fruit and vegetables). Its concentration is particularly high in human milk (on average approximately 600 micrograms in milk over a 24-hour period) where it performs a very important function for babies. In babies, in fact, the mucous membranes of the digestive tract are not perfectly formed and the spermidine contained in the milk promotes growth of the epithelium of the gastric and intestinal mucous membranes.

Spermine derives biosynthetically from spermidine, via the action of specific amino-propylic radical donor enzymes, which transform the putrescine, common precursor, firstly into N-monoaminopropyl derivative (spermidine) and then into N,N'-diaminopropyl symmetric derivative (spermine). Spermidine is therefore the biosynthetic precursor of spermine.

Spermidine and spermine therefore represent important cell growth and proliferation factors.

According to the present invention it has now surprisingly been found that a preparation containing spermine or spermidine, whether administered orally or applied to the skin, stimulates the cells of the skin and skin appendages such as hairs, hair and nails, with consequent promotion of growth and regeneration of the
cells. The consequence is an effect that improves both the appearance and functional characteristics of the skin and skin appendages and combats ageing.

The subject of the present invention is therefore use of the polyamines spermine and spermidine, as is or in salified form, as the active ingredient in preparation of compositions for dietary, pharmaceutical or cosmetic use in humans, aimed at maintaining health and beauty of the skin and skin appendages and combating ageing.

The subject of the present invention is also a composition for pharmaceutical, dietary or cosmetic use for use in humans to maintain health and beauty of the skin and skin appendages and combat ageing, characterised in that it comprises as active ingredient spermine, spermidine or their salts.

Said composition can comprise as active ingredient spermine or spermidine or both, in free or salified form.

For a better understanding of the characteristics and advantages of the invention, the details of an experimental study giving rise to said invention are now described.

THE CLINICAL STUDY

The study determined some of the fundamental indexes of health and functionality of the skin and skin appendages. In order to verify the effect of the substances being studied, the following parameters, considered to be of great importance, were identified and assessed:

hydration
elasticity
cell renewal

Assessment of hydration and elasticity

The effectiveness of the product was assessed *in vivo* by testing in use, carried out on 20 adult consenting volunteers (aged between 18 and 55).

On the forearms of each volunteer 3 areas were selected:

- one for application of the product being studied containing spermidine;
- one for application of the product being studied without spermidine;
- one as a control area.
A composition for topical use according to the invention (composition containing spermidine) and a product without spermidine (placebo) are given to the subjects who will apply them, according to the procedures indicated above, twice a day for 1 month.

5 At the beginning and at the end of the test the following instrumental assessments of effectiveness are performed:
- skin hydration by means of corneometer
- skin elasticity by means of cutometer

For each area (product, placebo, control) the values recorded at the beginning of the test were compared, via appropriate statistical processing, with the data obtained at the end of the test. The variations obtained in the area treated with the product were further compared with those recorded at the place of application of the placebo.

The results showed an increase in skin hydration with a statistically significant difference between the mean values observed after treatment and the corresponding values observed after the placebo. The degree of hydration, determined by electric capacitance measured with the corneometer, increased by over 10% with a high statistical significance (p<0.001).

The values recorded with the cutometer highlighted also in this parameter statistically significant differences (+20%; p<0.001) between the elasticity values before and after the treatment, also taking account of the effect due to the placebo preparation.

Assessment of cell renewal

On the forearms of each volunteer 3 areas were selected, on each of which a 5% suspension of dansyl chloride in vaseline was applied (with occlusive bandaging for 20 ± 4 hours). The following day the patches were removed and the 3 skin areas were examined under a quartz UV lamp to assess the degree of fluorescence induced by the dansyl chloride. Using a numerical reference scale, a score was assigned to the intensity of each spot.

The subjects were then given the composition of the invention and the placebo, with the recommendation to apply them as follows:
- in the first area the product containing spermidine;
- in the second area the product without spermidine;
- in the third area no product as it is the control area.

The volunteers applied the samples twice a day and were recalled regularly to the laboratory until complete disappearance of the fluorescent spots. At the beginning and end of the test, corresponding to the 2 areas selected, the quantity of superficial corneocytes was measured by means D-Squame (transparent adhesive discs).

The effectiveness of cell renewal was expressed as the number of days required to induce disappearance of the fluorescence in the areas treated (with the product or with the placebo) with respect to the control area. The statistical analysis highlighted shortening of the cell renewal period in the order of 20% (p<0.01).

EXAMPLES
Some non-restrictive examples of the composition according to the invention are now described.

EXAMPLE 1
DIETARY COMPOSITION FOR ORAL USE FOR HEALTH AND BEAUTY OF SKIN AND NAILS.

TABLETS.
Each tablet contains:

20 Methyl sulfonyl methane  200 mg
Spermidine trihydrochloride  0.25 mg
Vitamin C  61.86 mg
Vitamin E (dl-alfa tocopherol)  32.89 mg
Vitamin B6 (Pyridoxine)  3.65 mg
25 Calcium d-Panthenol  4 mg
d-Biotin  0.23 mg
Zinc aminoacid chelate  37.5 mg
Copper aminoacid chelate  12 mg
Manganese aminoacid chelate  22.5 mg
30 Selenium yeast 2000 µg/g 13.75 mg
Microcrystalline cellulose  120 mg
Calcium phosphate dibasic dihydrate  98.89 mg
Hydroxypropyl methylcellulose  52.5 mg
Magnesium stearate        8 mg
Silicon dioxide          3.5 mg

EXAMPLE 2

5 DIETARY COMPOSITION FOR ORAL USE FOR HEALTH AND BEAUTY OF SKIN EXPOSED TO RADIATION.

TABLETS.

Each tablet contains:
Spermidine trihydrochloride  0.25 mg

10 Calcium panthotenate     4 mg
Ubidecarenone         10 mg
Vitamin C             62 mg
Vitamin E (dl-alfa tocopherol)  33 mg
Beta-Carotene         36 mg

15 Vitamin B6 (Pyridoxine)  3.65 mg
d-Biotin               0.225 mg
Zinc aminoacid chelate  37.5 mg
Copper aminoacid chelate 12 mg
Manganese aminoacid chelate 17.5 mg

20 Calcium phosphate dibasic dihydrate  120 mg
Microcrystalline cellulose  259.38 mg
Hydroxypropyl methylcellulose  56 mg
Magnesium stearate        7 mg
Silicon dioxide          1.75 mg

25 EXAMPLE 3

COSMETIC COMPOSITION FOR TOPICAL SKIN TREATMENT.

EMULSION.

100 ml of emulsion contain:
Spermidine trihydrochloride  0.02 g

30 Emulgade SE (Glyceryl Stearate, Ceteareth-20, Ceteareth-12, Cetearyl alcohol, Cetyl palmitate)  4.5 g
Ceteareth 201 g
Coco-caprylate/caprate 5 g
Dicaprylyl ether 5 g
Water q.s. to 100 ml

EXAMPLE 4

5 COSMETIC COMPOSITION FOR TOPICAL SKIN TREATMENT WITH SUN FILTER.
LOTION APPLICABLE ALSO IN SPRAY.

100 ml of lotion contain:
Spermidine trihydrochloride 0.01 g

10 Emulgade SE (Glyceryl Stearate, Ceteareth-20, Ceteareth-12, Cetearyl alcohol,
Cetyl palmitate) 3.9 g
Ceteareth 203.1 g
Coco-caprylate/caprate 7 g
Octyl methoxycinnamate 4 g

15 Isoamyl methoxycinnamate 6 g
Benzophenone-3 2 g
Tocopherol 0.5 g
Glycerol 5 g
Preservative, fragrance q.s.

20 Water 64.5 g
CLAIMS

1 - Use of spermine and/or spermidine in free or salified form as active principle in the preparation of a composition for dietary, pharmaceutical or cosmetic use in humans for health and beauty of the skin and skin appendages, to combat ageing thereof.

2 – Use of spermine and/or spermidine in free or salified form as active principle in the preparation of a composition for dietary, pharmaceutical or cosmetic use in humans so as to improve at least one of the following properties of the human skin: hydration, elasticity, cell renewal.

3 - Composition for pharmaceutical or dietary or cosmetic use for administration in humans for health and beauty of the skin and skin appendages characterised in that it comprises as active principle spermine or spermidine or both, in free or salified form.

4 - Composition for pharmaceutical or dietary or cosmetic use for administration in humans so as to improve at least one of the following properties of the human skin: hydration, elasticity, cell renewal, characterised in that it comprises as active principle spermine or spermidine or both, in free or salified form.

5 - Composition according to claims 3 and 4, characterised in that it also comprises methyl sulfonyl methane or methionine, vitamin C, vitamin E, Vitamin B6, calcium d-panthotenate, d-biotin, zinc (as aminoacid chelate), copper (as aminoacid chelate), manganese (as aminoacid chelate) and a source of organic selenium.

6 - Composition according to claims 3 and 4, characterised in that it comprises:
   Methyl sulfonyl methane  200 mg
   Spermidine trihydrochloride  0.25-0.5 mg
   Vitamin C  60-90 mg
   Vitamin E (dl-alfa tocopherol)  33 mg
   Vitamin B6 (Pyridoxine)  3.7 mg
   Calcium d-Panthotenate  4 mg
   d-Biotin  0.23 mg
   Zinc (as aminoacid chelate)  7.5 mg
   Copper (as aminoacid chelate)  1.25 mg
Manganese (as aminoacid chelate)  2.25 mg
Selenium (as Se yeast)  0.03 mg

7 - Composition according to claims 3 and 4, characterised in that it is suitable for oral administration.

5  8 - Composition according to claims 3 and 4, characterised in that it is suitable for topical administration, such as a lotion or cream.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K7/48 A61K31/13 A23L1/305 A61P17/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61L A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, CHEM ABS Data, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 4 507 321 A (RAISFELD ILENE H) 26 March 1985 (1985-03-26) claims; examples</td>
<td>1-4,7,8</td>
</tr>
<tr>
<td>X</td>
<td>WO 94/12464 A (CHARONIS ARISTIDIS S ; FURCHT LEO T (US); CANELLAKIS EVANGELO (GR); TS) 9 June 1994 (1994-06-09) page 11, line 20 - line 22; claims</td>
<td>1-4,7,8</td>
</tr>
<tr>
<td>X</td>
<td>WO 99/51213 A (ILENCHUK THEODORE TONEY ; MADDIN WILLIAM STUART (CA)) 14 October 1999 (1999-10-14) page 12, last paragraph - page 13, paragraph 1; claims; examples</td>
<td>1-4,7,8</td>
</tr>
<tr>
<td>X</td>
<td>EP 0 884 046 A (LEE DE NV SARA) 16 December 1998 (1998-12-16) the whole document</td>
<td>1-4,8</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

** Special categories of cited documents:

**A** document defining the general state of the art which is not considered to be of particular relevance

**E** earlier document but published on or after the international filing date

**L** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

**O** document referring to an oral disclosure, use, exhibition or other means

**P** document published prior to the international filing date but later than the priority date claimed

**T** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

**X** document of particular relevance; the claimed invention cannot be considered as novel or cannot be considered to involve an inventive step when the document is taken alone

**Y** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Date of the actual completion of the international search

9 December 2004

Date of mailing of the international search report

29/12/2004

Name and mailing address of the ISA
European Patent Office, P.B. 5618 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016

Authorized officer
Minas, S

Form PCT/ISA/310 (second sheet) (January 2004)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 98/06376 A (REVLON CONSUMER PROD CORP) 19 February 1998 (1998-02-19) page 10, line 1 - line 29; claims 18-20; examples</td>
<td>1-4,8</td>
</tr>
<tr>
<td>X</td>
<td>WO 96/23490 A (HAHN GARY SCOTT; COSMEDERM TECHNOLOGIES (US); THUESON DAVID OREL (US)) 8 August 1996 (1996-08-08) claims 1,2</td>
<td>3,4,8</td>
</tr>
<tr>
<td>P,X</td>
<td>WO 03/063851 A (SORBELLI ELISABETTA; RINALDI FABIO (IT); GATTI VALTER (IT); GIULIANI) 7 August 2003 (2003-08-07) the whole document</td>
<td>1,3,4,7,8</td>
</tr>
<tr>
<td>A</td>
<td>WO 02/15860 A (IOANNIDES TIM) 28 February 2002 (2002-02-28) claims</td>
<td>1-8</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>US 4507321</td>
<td>26-03-1985</td>
<td>NONE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9412464 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2326614 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9951213 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1075254 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2002510618 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 4067497 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5925366 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9806376 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 9707362 A</td>
</tr>
<tr>
<td>WO 9623490</td>
<td>08-08-1996</td>
<td>AU 4861196 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2212127 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 10513452 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9623490 A1</td>
</tr>
<tr>
<td>JP 2003113047</td>
<td>18-04-2003</td>
<td>NONE</td>
</tr>
<tr>
<td>JP 7268323</td>
<td>17-10-1995</td>
<td>NONE</td>
</tr>
<tr>
<td>WO 03063851</td>
<td>07-08-2003</td>
<td>IT MI20020189 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2473160 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 03063851 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1469843 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6524593 B1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6159485 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2004089329 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 775209 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2408000 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 0007430 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2358457 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1336817 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2002534369 T</td>
</tr>
<tr>
<td>WO 0215860</td>
<td>28-02-2002</td>
<td>AU 8657801 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0215860 A1</td>
</tr>
</tbody>
</table>